Brought to you by 
Phagenesis closes its $9.4mm Series B venture round; expanded to $17mm
23 May 2013
Executive Summary
Phagenesis Ltd. has raised €7mm ($9.4mm) through the closing of its Series B venture round. Inventages led and was joined by current shareholders. The company is developing a device to treat acute and chronic dysphagia (the inability to swallow).
Deal Industry
- Medical Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Phagenesis closes its $9.4mm Series B venture round; expanded to $17mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice